GAMMA Investing’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

GAMMA Investing’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-750	Closed	-$98.9K	–	3923
2025 Q1	$98.9K	Sell	750 -8	-1%	-$997	0.01%	1266
2024 Q4	$63.3K	Buy	758 +240	+46%	+$19.7K	0.01%	1471
2024 Q3	$37.9K	Buy	518 +117	+29%	+$8.79K	﹤0.01%	1691
2024 Q2	$27.5K	Buy	401 +104	+35%	+$7.21K	﹤0.01%	1648
2024 Q1	$20.6K	Buy	297 +42	+16%	+$2.89K	﹤0.01%	1639
2023 Q4	$17.2K	Buy	+255	New	+$14.7K	﹤0.01%	1600

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

GAMMA Investing's ITCI Position: Q2 2025 in Review

GAMMA Investing sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 750 shares — an estimated $98.9K sold.

GAMMA Investing first reported a position in ITCI in Q4 2023 and held it in 6 quarters. The position peaked at $98.9K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

GAMMA Investing reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
GAMMA Investing sold 750 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $98.9K.
GAMMA Investing first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 6 quarters.
GAMMA Investing's Intra-Cellular Therapies Inc. position peaked at $98.9K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on GAMMA Investing's 13F filing for Q2 2025, filed 14 Jul 2025.